It is important to characterize the different clinical and biochemical profiles of these patients, since the identification of treatments with a greater effect on tumor size and on biochemical control in patients with GH/PRL PitNETs (or the ones that will be resistant to medical therapy) would allow us to implement a personalized approach, leading to earlier and better control of the disease. Here, PRL is linked to neoplasm.